219: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer...

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.


In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.


Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.


In this episode, you’ll learn about:

• The historical and current challenges in characterizing these interactions at scale (06:22)
• How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)
• A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)
• The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)
• Real-world examples of how A-Alpha Bio’s approach is compressing years of work into months without sacrificing quality (13:58)
• The science behind A-Alpha Bio’s AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)
• The practical affinity range the technology can measure, covering most therapeutic applications (23:25)

Whether you’re a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.


Connect with Troy Lionberger:


LinkedIn: www.linkedin.com/in/troylionberger (  / troylionberger  )


A-Alpha Bio website: www.aalphabio.com (https://www.aalphabio.com/technology/)


Next step:


Need fast CMC guidance? → Get rapid CMC decision support here (https://stan.store/SmartBiotech/p/ond...)


One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk (https://stan.store/SmartBiotech/p/don...) before it gets expensive. Two slots open this month.


Support the show (https://www.buzzsprout.com/2263581/su...)